Rapport Therapeutics, Inc. Common Stock
RAPP
Rank in Stocks
#7737
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical... Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Share Price
$26.07
Last synced: 2026-11-09
Market Cap
$1.25B
Change (1 day)
6.67%
Change (1 year)
3.58%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Rapport Therapeutics, Inc. Common Stock (RAPP)
Category
Healthcare
EPS for Rapport Therapeutics, Inc. Common Stock (RAPP)
EPS as of September 2026 TTM: $-3.17
According to Rapport Therapeutics, Inc. Common Stock's latest financial reports, its current EPS (TTM) is $-3.17. At the end of 2025 the company had an EPS of $-2.86, an increase over its 2024 EPS of $-3.78.
EPS history for Rapport Therapeutics, Inc. Common Stock from 2022 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.17 | 10.84% |
| 2025 | $-2.86 | -24.34% |
| 2024 | $-3.78 | 297.89% |
| 2023 | $-0.95 | 227.59% |
| 2022 | $-0.29 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -594.01% |
US
|
|
| $-7.07 | 123.03% |
US
|
|
| $-5.29 | 66.88% |
AU
|
|
| $12.88 | -506.31% |
BE
|
|
| $21.56 | -780.13% |
NL
|
Questions about Rapport Therapeutics, Inc. Common Stock's earnings per share (EPS)
What is Rapport Therapeutics, Inc. Common Stock's earnings per share (EPS)?
Rapport Therapeutics, Inc. Common Stock's earnings per share (EPS) over the last twelve months is $-3.17, as of Sep 2026.
What was Rapport Therapeutics, Inc. Common Stock's earnings per share (EPS) in 2025?
In 2025, Rapport Therapeutics, Inc. Common Stock's earnings per share (EPS) was $-2.86, compared with $-3.78 in 2024.
How has Rapport Therapeutics, Inc. Common Stock's earnings per share (EPS) changed since 2022?
From 2022 to 2025, Rapport Therapeutics, Inc. Common Stock's earnings per share (EPS) was highest in 2022 ($-0.29) and lowest in 2024 ($-3.78).
How does Rapport Therapeutics, Inc. Common Stock's earnings per share (EPS) compare with similar companies?
Rapport Therapeutics, Inc. Common Stock's earnings per share (EPS) ($-3.17) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.